Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc.
Your view on RANI
Overview
What the company does, where it operates, and who runs it.
About Rani Therapeutics Holdings, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Talat Imran
- Headquarters
- 2051 Ringwood Avenue, San Jose, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Talat Imran
- Headquarters
- 2051 Ringwood Avenue, San Jose, CA, US
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing.
Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes.
The company was incorporated in 2012 and is headquartered in San Jose, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Rani Therapeutics Holdings, Inc., and the rating behind it. RANI last traded at $0.84; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Rani Therapeutics Holdings, Inc.. Starting points for Rani Therapeutics Holdings, Inc.: EPS -$0.16, beta 0.70 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Rani Therapeutics Holdings, Inc.. Rani Therapeutics Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Rani Therapeutics Holdings, Inc.. Trailing twelve-month EPS for Rani Therapeutics Holdings, Inc. stands at -$0.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Rani Therapeutics Holdings, Inc.. Rani Therapeutics Holdings, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Rani Therapeutics Holdings, Inc. valued side by side against its closest peers. Rani Therapeutics Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Rani Therapeutics Holdings, Inc., and how their positions are changing. At a $55.0M market value, institutional positions materially move Rani Therapeutics Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Rani Therapeutics Holdings, Inc. executives and directors. Shares of Rani Therapeutics Holdings, Inc. have traded between $0.39 and $3.87 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Rani Therapeutics Holdings, Inc.. Rani Therapeutics Holdings, Inc. is a $55.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Rani Therapeutics Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Rani Therapeutics Holdings, Inc.. Coverage tracks Rani Therapeutics Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.